The Clinical Oncology Society of Australia (COSA) has called for “exercise to be embedded as part of standard practice in cancer care and to be viewed as an adjunct therapy that helps counteract the adverse effects of cancer and its treatment.” - https://t.co/b4qbsHtLr2
THE LANCET ONCOLOGY: [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. https://t.co/VA6aCw71jF
PATIENT POV - The Sydney Morning Herald also published an article about Lutetium-177 PSMA therapy, interviewing a 76yo patient who "had exhausted all conventional treatments but one". Read More>>> https://t.co/zFyDrw9X63
MEN'S HEALTH - The Australian Financial Review has recently published an article about Lutetium-177 PSMA therapy, a theranostics approach to treating mCRPC. Read More>>> https://t.co/qnux711eNy
ARTICLE OF THE WEEK: "Recent advances in theranostics and challenges for the future." - A/Prof. Harvey Turner (Perth, Western Australia).
Read Here>>>https://t.co/hmniWjjD4R
Congratulations to the #WFNMB and all parties involved in the success of the 12th World Congress of the World Federation of Nuclear Medicine & Biology in Melbourne, Australia. We look forward to the 13th World Congress of the WFNMB to be hosted in Kyoto, Japan (2022).
Theranostics Australia would like to congratulate Prof Harvey Turner on his Pioneer Lecture “Global harmonization of clinical practice of theranostic nuclear oncology” presented at the #WFNMB2018 for the Australian and New Zealand Society of Nuclear Medicine (ANZSNM).
Theranostics Australia will be hosting a breakfast session tomorrow at the #WFNMB2018 Conference - “Next Generation Theranostics”. We are thrilled to have Prof Dale Bailey, Prof Kate Vallis, Dr Matt Harris and Dr Danielle Meyrick speaking about the future of theranostics.
Theranostics Australia’s Ms Julie Crouch (National Operations Manager) will be presenting today at the #WFNMB2018 Conference within the ANZSNM Technologist SIG session. Best of luck to all the speakers involved.
Theranostics Australia is proud to be a Supporting Partner of the 12th World Congress of the World Federation of Nuclear Medicine & Biology in Melbourne, April 20 - 24 2018 >> https://t.co/4pFau6HPxv #WFNMB2018
We only have 10 days to go until #WFNMB2018 ! If you haven't already registered, it's not too late! Register today so you don't miss out on the BEST nuclear medicine event in Australia! https://t.co/fY8bpfKqsJ